A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy
← catalyst calendarSponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 3
Status
Completed
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
580actual
Sites
224
Countries
Australia, Austria, Belgium +20
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-12-14 | actual | When the study began enrolling |
| Primary completion | 2025-03-06 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-10-20 | actual | The whole study's end, after follow-up |
| First posted | 2022-10-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-11-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Cardiomyopathy, Hypertrophic
Interventions
- Drug: Mavacamten — also filed as BMS-986427, MYK-461
- Other: Placebo
Primary outcomes
what the primary-completion date above is the date OFChange from baseline in Kansas City Cardiomyopathy Questionnaire (23-item) Clinical Summary Score (KCCQ-23 CSS) at Week 48
measured Up to Week 48
Change from baseline in peak oxygen consumption (pVO2) at Week 48
measured Up to Week 48
Publications
- PMID 40888717 — linked by the registry
- PMID 40864018 — linked by the registry
- PMID 40425241 — linked by the registry
- PMID 39909647 — linked by the registry
- PMID 38625800 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed